AMO Pharma in Collaboration with Population Health Research Institute (PHRI) and Venca Research Inc. Announces FDA Advice on Potential Phase 3 Development Path for AMO-02 in Treatment of Arrhythmogenic Cardiomyopathy (ACM)
AMO Pharma, with the Population Health Research Institute and Venca Research, announced FDA advice on a potential Phase 3 development path for AMO-02 in arrhythmogenic cardiomyopathy.